Basepoint Chepstow Welcomes European biotech company
The Team at Basepoint Chepstow are delighted to have welcomed new Licensee Apitope Technology Ltd to our Centre.
Apitope, led by CEO Dr. Keith F Martin, is a European biotech company focused on the discovery and development of revolutionary disease modifying therapies for autoimmune and allergic diseases. Apitope’s mission is to develop novel therapeutics that directly target the underlying cause of allergy and autoimmune disease.
Chloe Geoghegan, Assistant Centre Manager at Basepoint Chepstow, said “We first met Dr. Martin and his team over the summer and we were delighted when they chose Basepoint Chepstow as their preferred location. We look forward to getting to know the team and to supporting their flourishing business”.
To find out more about Apitope please visit their website.